HIV and hepatitis B coinfection follow-up study in Europe
Part of Digestive system, Immune system & allergy, Infections clinical trials.
This study follows people who have both HIV and hepatitis B over time to better understand how the infection responds after starting treatment. Your information (and sometimes stored blood samples) helps researchers track changes from the start of therapy to about 2 years later.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are part of a participating (contributing) study cohort
- You have a hepatitis B test called HBsAg that is positive at least twice, with the tests more than 6 months apart
- You have at least one set of information at the start of treatment and additional information about 2 years later after starting TDF or TAF
- The 2-year information can be from regular study visits or from stored samples
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This research study follows people with hepatitis B (a liver infection) in Zambia to understand how their bodies respond to treatment and what happens to the virus over time. It includes people with hepatitis B alone, those also living with HIV, and those whose hepatitis B has cleared.
This study follows people living with HIV who also have hepatitis C antibodies, to better understand how HIV and hepatitis C affect health over time. You may be able to join if you meet the age and enrollment requirements, even if your hepatitis C virus level is currently undetectable.
This study tests whether people with both HIV and hepatitis B (HBV) can safely stop or switch parts of their antiviral treatment. It aims to see if simpler treatment can keep both viruses under control for 96 weeks.
This study follows people with hepatitis B (HBV) blood tests that have improved over the last year. It aims to learn what happens after the hepatitis B surface antigen (HBsAg) goes down, and may help doctors better predict outcomes.
This study builds a group of people to measure small hepatitis B “viral RNA” signals in the blood. The goal is to see if these measurements could help researchers find a functional cure and better understand who may respond over time.
This study is looking for people in south-east Austria who have hepatitis B (HBV) or hepatitis C (HCV) that hasn't been fully treated or documented. It aims to find how many people also have hepatitis D (HDV) and are not yet aware of it.
Hear when a new HIV Infections trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.